CoChat

Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis

Open access

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

Abelson kinase (c‐abl) and platelet‐derived growth factor (PDGF) are key players in the pathogenesis of systemic sclerosis (SSc). The aim of the present study was to evaluate the antifibrotic potential of dasatinib and nilotinib, 2 novel inhibitors of c‐abl and PDGF, which are well tolerated and have recently been approved. Dasatinib and nilotinib dose‐dependently reduced the mRNA and protein levels of extracellular matrix proteins in human stimulated dermal fibroblasts from SSc patients (IC 50 of 0.5–2.0 nM for dasatinib and 0.8–2.5 nM for nilotinib). In a mouse model of bleomycin‐induced dermal fibrosis, dasatinib and nilotinib potently reduced the dermal thickness, the number of myofibroblasts, and the collagen content of the skin in a dose‐dependent manner at well‐tolerated doses. These data indicate that dasatinib and nilotinib potently inhibit the synthesis of extracellular matrix in vitro and in vivo at biologically relevant concentrations. Thus, we provide the first evidence that dasatinib and nilotinib might be promising drugs for the treatment of patients with SSc.—Akhmetshina, A., Dees, C., Pileckyte, M., Maurer, B., Axmann, R., Jüngel, A., Zwerina, J., Gay, S., Schett, G., Distler, O., Distler, J. H. W. Dual inhibition of c‐abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J. 22, 2214–2222 (2008)

Overview

Integrity signals

Registry

Crossref · 10.1096/fj.07-105627

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

The citation lists are queued

They are fetched later and appear here then.

References 30 · Cited by 187

Metadata

Authors
Akhmetshina, A., Dees, C., Pileckyte, M., Maurer, B., Axmann, R., Jüngel, A., Zwerina, J., Gay, S., Schett, G., Distler, O., & Distler, J. H. W.
Affiliations
  • Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
  • Department of Rheumatology Kaunas Medical University Hospital Kaunus Lithuania
  • University of Zurich (CH)
Venue
The FASEB Journal
Publisher
Wiley
Published
2008-03-07
Volume
22
Issue
7
Pages
2214-2222
ISSN
  • 0892-6638 (ISSN-L)
  • 1530-6860
OpenAlex
W2030619805
Cited by
187
References
30
Citations by year
2026: 2 · 2025: 2 · 2024: 2 · 2023: 4 · 2022: 3 · 2021: 6 · 2020: 6 · 2019: 13 · 2018: 10 · 2017: 15 · 2016: 10 · 2015: 11 · 2014: 4 · 2013: 12 · 2012: 21
FWCI
15.61
Type
journal article
Language
en
Open access
Locations
  • The FASEB Journal (publishedVersion)
  • PubMed (publishedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
  • Lithuanian University of Health Sciences (submittedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
  • Zurich Open Repository and Archive (University of Zurich)
Funders
  • Elan (53410022)
  • German-Russian Interdisciplinary Science Center (A20)
Topics
  • Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
  • Health Sciences › Medicine › Rheumatology › Dupuytren's Contracture and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Connective tissue disorders research
Keywords
dasatinib, nilotinib, c-Abl kinase, PDGF receptor, systemic sclerosis, skin fibrosis, antifibrotic therapy, extracellular matrix synthesis, dermal fibroblasts, myofibroblasts, bleomycin-induced fibrosis, tyrosine kinase inhibitors
MeSH terms
Dasatinib, Adult, Aged, Biopsy, Cells, Cultured, Fibroblasts, Humans, Middle Aged, Pyrimidines, Scleroderma, Systemic, Skin, Thiazoles, Signal Transduction, Proto-Oncogene Proteins c-abl, Receptors, Platelet-Derived Growth Factor, Age of Onset, Protein Kinase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. https://app.cochat.ai/papers/10.1096/fj.07-105627
The paper
Akhmetshina, A., Dees, C., Pileckyte, M., Maurer, B., Axmann, R., Jüngel, A., Zwerina, J., Gay, S., Schett, G., Distler, O., & Distler, J. H. W. (2008). Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. The FASEB Journal. https://doi.org/10.1096/fj.07-105627

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.